Depression is the leading cause of disability worldwide, despite the many pharmacological and non-pharmacological treatment options available. Treatment-resistant depression (TRD), which is often defined as an insufficient response to two or more adequate treatment trials, affects up to 50% of those with depression. TRD is associated with poorer prognosis, higher mortality, and higher healthcare utilisation costs. Given the heterogeneous nature of depression, a more personalised approach to treatment may improve prognosis in TRD. This session will explore conceptualisation of TRD, as well as recent advances in pharmacological and non-pharmacological treatment options.
This session will help you:
- Understand the varying conceptualisations of TRD, most notably 'difficult-to-treat' depression.
- Understand clinical guidelines for treating TRD, including pharmacological and non-pharmacological treatment options.
- Have an awareness of recent clinical trials that have sought to improve outcomes for those with TRD.
Chair: Anthony Cleare, King's College London, United Kingdom
Hamish McAllister-Williams, Newcastle University, United Kingdom
Anthony Cleare, King's College London, United Kingdom
